News

As part of the agreement, Merck will bear the costs involved in evaluating the candidate, which Arrowhead obtained from Alvos Therapeutics in April 2012. Arrowhead president and CEO

The patent was awarded based on FDA-authorised clinical study, which showed that the non-toxic dietary supplement (PHC) contributed to healthy outcome for men with recurrent prostate cancer. The

The screening service combines CeeTox in vitro toxicity screening and CDI’s iCell Cardiomyocytes to provide a profile of drug-induced cardiac toxicity early in the drug development cycle. CeeTox

Under the agreement, Zenobia will provide ADDF’s researchers with access to its discovery platform including a gene-to-structure platform with in-house cloning, expression and purification in E coli, insect

Proximagen’s pipeline includes many programs which are in various stages of development across a number of therapeutic classes including CNS, inflammation, oncology and ophthalmology. The acquisition will enable

The orphan drug designation was granted based on a plausible hypothesis for clinical superiority over the approved nitric oxide product. NO is delivered via the company’s GeNOsyl MVG-2000

Viokace, in combination with a proton pump inhibitor, is indicated in adults for the treatment of exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatectomy. Aptalis president and

Wockhardt will manufacture the Alfuzosin hydrochloride API in its Ankleshwar facility and the extended-release tablets of Alfuzosin at its facility in Aurangabad, India. The technology for the API

The collaboration will focus on three microRNA targets, which include Regulus’ lead cardiovascular/metabolic disease program targeting microRNA-33 for the treatment of atherosclerosis. According to the agreement, AstraZeneca will